|Pemirolast potassium Catalog No.GC17892|
Sample solution is provided at 25 µL, 10mM.
GlpBio Products Cited In Reputable Papers
|Solubility||≥85.4mg/mL in H2O||Storage||Store at -20°C|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
|Shipping Condition||Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
Pemirolast potassium (TWT-8152) is a histamine H1 antagonist and mast cell stabilizer that acts as an antiallergic agent.Target: Histamine H1 ReceptorPemirolast potassium (TWT-8152) is a new oral, nonbronchodilator antiallergy medication that is being evaluated for the therapy of asthma . Pemirolast potassium (TWT-8152) inhibits chemical mediator release from tissue mast cells and is also shown to inhibit the release of peptides including substance P, Pemirolast potassium (TWT-8152) reduces kaolin intake by inhibition of substance P release in rats . Pemirolast potassium (TWT-8152) potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats . Pemirolast potassium (TWT-8152) potassium is used for the treatment of allergic conjunctivitis and prophylaxis for pulmonary hypersensitivity reactions to drugs such as paclitaxel .
. Kemp, J.P., et al., Pemirolast, a new oral nonbronchodilator drug for chronic asthma. Ann Allergy, 1992. 68(6): p. 488-91.
. Tatsushima, Y., et al., Pemirolast reduces cisplatin-induced kaolin intake in rats. Eur J Pharmacol, 2011. 661(1-3): p. 57-62.
. Itoh, Y., et al., Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats. Neuropharmacology, 2004. 46(6): p. 888-94.
. Abelson, M.B., et al., Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies. J Ocul Pharmacol Ther, 2002. 18(5): p. 475-88.